Healthcare stocks slightly lower today were with the NYSE
Healthcare Sector Index slipping about 0.3% and shares of
healthcare companies in the S&P 500 also down about 0.5% as a
In company news, Amicus Therapeutics (
) rallied Monday, with shares of the biotech and drug-maker jumping
to a 17-month high after saying a late-stage study of its
migalastat HCl monotherapy for Fabry patients is now complete, with
top-data due out during the next three months.
Farbry disease is a rare genetic lysosomal storage disease
causing a wide range of systemic symptoms such as full-body or
localized pain, often first experienced in early childhood. FOLD
said if the now completed study is successful, it will soon begin
the process of seeking European regulatory approval, followed by
discussions with the Food and Drug Administration before the end of
"Hopefully, migalastat will become an important new medicine for
the treatment of Fabry disease, where so much unmet need remains,"
CEO John Crowley said in prepared remarks.
FOLD shares were up almost 10% at $3.33 apice late in today's
session, earlier climbing as high as $4.06 a share, up nearly 34%.
Heading into Monday trading, the stock has risen 31.2% over the
past 12 months through Friday's close.
In other sector news,
(+) DRNA, Announces positive preclinical data for its DCR-PH1
drug candidate to treat primary hyperoxaluria type 1, a rare,
inherited liver disorder causing progressive kidney damage.
(-) RMD, Cautious mention this weekend in Barron's, which writes
the company's shares could fall as much as 15% if the federal
government sides with proposals to cut its reimbursement for home
medical care costs.